+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Actinic Keratosis Drugs Market 2021-2025- Product Image
Global Actinic Keratosis Drugs Market 2021-2025- Product Image

Global Actinic Keratosis Drugs Market 2021-2025

  • ID: 5117604
  • Report
  • April 2021
  • Region: Global
  • 120 pages
  • TechNavio

FEATURED COMPANIES

  • 3M Co.
  • Almirall SA
  • Biofrontera AG
  • Hill Dermaceuticals Inc.
  • Mylan NV
  • Vidac Pharma
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The publisher has been monitoring the actinic keratosis drugs market and it is poised to grow by $709.82 million during 2021-2025, progressing at a CAGR of about 4% during the forecast period. The report on the actinic keratosis drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the high prevalence of actinic keratosis and the threat of conversion to fatal disease.

The actinic keratosis drugs market analysis includes the product segment and geographic landscape.

The actinic keratosis drugs market is segmented as below:

By Product
  • Nucleoside metabolic inhibitors
  • Immunomodulators
  • Photosensitizers
  • NSAIDs
By Geography
  • North America
  • APAC
  • Europe
  • ROW
This study identifies the availability of combination therapy as one of the prime reasons driving the actinic keratosis drugs market growth during the next few years.

The report on actinic keratosis drugs market covers the following areas:
  • Actinic keratosis drugs market sizing
  • Actinic keratosis drugs market forecast
  • Actinic keratosis drugs market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading actinic keratosis drugs market vendors that include 3M Co., Almirall SA, Bausch Health Companies Inc., Biofrontera AG, Cipher Pharmaceuticals Inc., Hill Dermaceuticals Inc., Mylan NV, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Vidac Pharma. Also, the actinic keratosis drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • 3M Co.
  • Almirall SA
  • Biofrontera AG
  • Hill Dermaceuticals Inc.
  • Mylan NV
  • Vidac Pharma
Executive Summary
  • Market Overview
Market Landscape
  • Market ecosystem
  • Market characteristics
  • Value chain analysis
Market Sizing
  • Market definition
  • Market segment analysis
  • Market size 2020
  • Market outlook: Forecast for 2020 - 2025
Five Forces Analysis
  • Five forces summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
Market Segmentation by Product
  • Market segments
  • Comparison by Product
  • Nucleoside metabolic inhibitors - Market size and forecast 2020-2025
  • Immunomodulators - Market size and forecast 2020-2025
  • Photosensitizers - Market size and forecast 2020-2025
  • NSAIDs - Market size and forecast 2020-2025
  • Market opportunity by Product
Customer landscape

Geographic Landscape
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2020-2025
  • APAC - Market size and forecast 2020-2025
  • Europe - Market size and forecast 2020-2025
  • ROW - Market size and forecast 2020-2025
  • Key leading countries
  • Market opportunity by geography
  • Market drivers
  • Market challenges
  • Market trends
Vendor Landscape
  • Overview
  • Landscape disruption
Vendor Analysis
  • Vendors covered
  • Market positioning of vendors
  • 3M Co.
  • Almirall SA
  • Bausch Health Companies Inc.
  • Biofrontera AG
  • Cipher Pharmaceuticals Inc.
  • Hill Dermaceuticals Inc.
  • Mylan NV
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Vidac Pharma
Appendix
  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations
List of Exhibits

Exhibits1: Key Finding 1

Exhibits2: Key Finding 2

Exhibits3: Key Finding 3

Exhibits4: Key Finding 5

Exhibits5: Key Finding 6

Exhibits6: Key Finding 7

Exhibits7: Key Finding 8

Exhibits8: Parent market

Exhibits9: Market characteristics

Exhibits10: Offerings of vendors included in the market definition

Exhibits11: Market segments

Exhibits12: Global - Market size and forecast 2020 - 2025 ($ million)

Exhibits13: Global market: Year-over-year growth 2020 - 2025 (%)

Exhibits14: Five forces analysis 2020 & 2025

Exhibits15: Bargaining power of buyers

Exhibits16: Bargaining power of suppliers

Exhibits17: Threat of new entrants

Exhibits18: Threat of substitutes

Exhibits19: Threat of rivalry

Exhibits20: Market condition - Five forces 2020

Exhibits21: Product - Market share 2020-2025 (%)

Exhibits22: Comparison by Product

Exhibits23: Nucleoside metabolic inhibitors - Market size and forecast 2020-2025 ($ million)

Exhibits24: Nucleoside metabolic inhibitors - Year-over-year growth 2020-2025 (%)

Exhibits25: Immunomodulators - Market size and forecast 2020-2025 ($ million)

Exhibits26: Immunomodulators - Year-over-year growth 2020-2025 (%)

Exhibits27: Photosensitizers - Market size and forecast 2020-2025 ($ million)

Exhibits28: Photosensitizers - Year-over-year growth 2020-2025 (%)

Exhibits29: NSAIDs - Market size and forecast 2020-2025 ($ million)

Exhibits30: NSAIDs - Year-over-year growth 2020-2025 (%)

Exhibits31: Market opportunity by Product

Exhibits32: Customer landscape

Exhibits33: Market share by geography 2020-2025 (%)

Exhibits34: Geographic comparison

Exhibits35: North America - Market size and forecast 2020-2025 ($ million)

Exhibits36: North America - Year-over-year growth 2020-2025 (%)

Exhibits37: APAC - Market size and forecast 2020-2025 ($ million)

Exhibits38: APAC - Year-over-year growth 2020-2025 (%)

Exhibits39: Europe - Market size and forecast 2020-2025 ($ million)

Exhibits40: Europe - Year-over-year growth 2020-2025 (%)

Exhibits41: ROW - Market size and forecast 2020-2025 ($ million)

Exhibits42: ROW - Year-over-year growth 2020-2025 (%)

Exhibits43: Key leading countries

Exhibits44: Market opportunity by geography ($ million)

Exhibits45: Impact of drivers and challenges

Exhibits46: Vendor landscape

Exhibits47: Landscape disruption

Exhibits48: Industry risks

Exhibits49: Vendors covered

Exhibits50: Market positioning of vendors

Exhibits51: 3M Co. - Overview

Exhibits52: 3M Co. - Business segments

Exhibits53: 3M Co. - Key offerings

Exhibits54: 3M Co. - Key customers

Exhibits55: 3M Co. - Segment focus

Exhibits56: Almirall SA - Overview

Exhibits57: Almirall SA - Product and service

Exhibits58: Almirall SA - Key offerings

Exhibits59: Almirall SA - Key customers

Exhibits60: Almirall SA - Segment focus

Exhibits61: Bausch Health Companies Inc. - Overview

Exhibits62: Bausch Health Companies Inc. - Business segments

Exhibits63: Bausch Health Companies Inc. - Key offerings

Exhibits64: Bausch Health Companies Inc. - Key customers

Exhibits65: Bausch Health Companies Inc. - Segment focus

Exhibits66: Biofrontera AG - Overview

Exhibits67: Biofrontera AG - Product and service

Exhibits68: Biofrontera AG - Key offerings

Exhibits69: Biofrontera AG - Key customers

Exhibits70: Biofrontera AG - Segment focus

Exhibits71: Cipher Pharmaceuticals Inc. - Overview

Exhibits72: Cipher Pharmaceuticals Inc. - Business segments

Exhibits73: Cipher Pharmaceuticals Inc. - Key offerings

Exhibits74: Cipher Pharmaceuticals Inc. - Key customers

Exhibits75: Cipher Pharmaceuticals Inc. - Segment focus

Exhibits76: Hill Dermaceuticals Inc. - Overview

Exhibits77: Hill Dermaceuticals Inc. - Product and service

Exhibits78: Hill Dermaceuticals Inc. - Key offerings

Exhibits79: Hill Dermaceuticals Inc. - Key customers

Exhibits80: Hill Dermaceuticals Inc. - Segment focus

Exhibits81: Mylan NV - Overview

Exhibits82: Mylan NV - Business segments

Exhibits83: Mylan NV - Key offerings

Exhibits84: Mylan NV - Key customers

Exhibits85: Mylan NV - Segment focus

Exhibits86: Sun Pharmaceutical Industries Ltd. - Overview

Exhibits87: Sun Pharmaceutical Industries Ltd. - Business segments

Exhibits88: Sun Pharmaceutical Industries Ltd. - Key offerings

Exhibits89: Sun Pharmaceutical Industries Ltd. - Key customers

Exhibits90: Sun Pharmaceutical Industries Ltd. - Segment focus

Exhibits91: Teva Pharmaceutical Industries Ltd. - Overview

Exhibits92: Teva Pharmaceutical Industries Ltd. - Business segments

Exhibits93: Teva Pharmaceutical Industries Ltd. - Key offerings

Exhibits94: Teva Pharmaceutical Industries Ltd. - Key customers

Exhibits95: Teva Pharmaceutical Industries Ltd. - Segment focus

Exhibits96: Vidac Pharma - Overview

Exhibits97: Vidac Pharma - Business segments

Exhibits98: Vidac Pharma - Key offerings

Exhibits99: Vidac Pharma - Key customers

Exhibits100: Vidac Pharma - Segment focus

Exhibits101: Currency conversion rates for US$

Exhibits102: Research Methodology

Exhibits103: Validation techniques employed for market sizing

Exhibits104: Information sources

Exhibits105: List of abbreviations
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • 3M Co.
  • Almirall SA
  • Biofrontera AG
  • Hill Dermaceuticals Inc.
  • Mylan NV
  • Vidac Pharma
The publisher recognizes the following companies as the key players in the global actinic keratosis drugs market: 3M Co., Almirall SA, Bausch Health Companies Inc., Biofrontera AG, Cipher Pharmaceuticals Inc., Hill Dermaceuticals Inc., Mylan NV, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Vidac Pharma.

Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is the availability of combination therapy.'

According to the report, one of the major drivers for this market is the high prevalence of actinic keratosis.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
  • 3M Co.
  • Almirall SA
  • Bausch Health Companies Inc.
  • Biofrontera AG
  • Cipher Pharmaceuticals Inc.
  • Hill Dermaceuticals Inc.
  • Mylan NV
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Vidac Pharma
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll